Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00292110 |
The purpose of this study is to determine if simultaneous abstinence from heroin and cocaine can be elicited by combining two approaches: flexible methadone dosing and voucher-based contingency management in which patients earn incentives for cocaine abstinence.
Condition | Intervention | Phase |
---|---|---|
Opiate-Related Disorders Cocaine-Related Disorders |
Behavioral: Contingency Management Drug: Methadone dose Behavioral: Contingency management/Noncontingent incentives Drug: Methadone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment |
Official Title: | Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management |
Estimated Enrollment: | 300 |
Study Start Date: | December 2004 |
Estimated Study Completion Date: | January 2012 |
Estimated Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Behavioral: Contingency Management
incentives given for cocaine abstinence
Drug: Methadone dose
flexible methadone dosing to 190 mg/day daily orally
|
2: Active Comparator |
Behavioral: Contingency Management
incentives given for cocaine abstinence
Behavioral: Contingency management/Noncontingent incentives
incentives given independent of drug use
Drug: Methadone
100 mg/day orally
|
3: Active Comparator |
Drug: Methadone dose
flexible methadone dosing to 190 mg/day daily orally
|
4: Active Comparator |
Behavioral: Contingency management/Noncontingent incentives
incentives given independent of drug use
Drug: Methadone
100 mg/day orally
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kenzie Preston, PhD | 410-550-1639 | kpreston@intra.nida.nih.gov |
United States, Maryland | |
NIDA Intramural Research Program | Recruiting |
Baltimore, Maryland, United States, 21224 | |
Principal Investigator: Kenzie Preston, PhD |
Principal Investigator: | Kenzie Preston, PhD | NIDA Intramural Research Program |
Responsible Party: | National Institute on Drug Abuse ( Kenzie L. Preston, Ph.D., Principal Investigator ) |
Study ID Numbers: | NIDAIRP 390, Z01 DA 000175 |
Study First Received: | February 14, 2006 |
Last Updated: | June 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00292110 |
Health Authority: | United States: Federal Government |
Naphazoline Cocaine-Related Disorders Oxymetazoline Methadone Guaifenesin Phenylephrine |
Heroin Mental Disorders Substance-Related Disorders Disorders of Environmental Origin Phenylpropanolamine Cocaine |
Respiratory System Agents Disease Physiological Effects of Drugs Central Nervous System Depressants Narcotics Pharmacologic Actions Pathologic Processes |
Sensory System Agents Therapeutic Uses Analgesics Peripheral Nervous System Agents Antitussive Agents Central Nervous System Agents Analgesics, Opioid |